Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Agenus Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
AGEN
Nasdaq
2830
www.agenusbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Agenus Inc.
Agenus to Participate in Upcoming September Investor Conferences
- Aug 31st, 2026 5:30 am
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
- Aug 28th, 2026 8:07 am
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
- Aug 26th, 2026 8:05 am
Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
- Aug 19th, 2026 8:31 am
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
- Aug 16th, 2026 7:07 am
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
- Aug 7th, 2026 3:45 pm
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
- Aug 6th, 2026 5:30 am
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
- Aug 4th, 2026 6:50 am
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
- Jul 30th, 2026 8:00 am
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
- Jul 28th, 2026 2:30 pm
Do Options Traders Know Something About Agenus Stock We Don't?
- Jul 23rd, 2026 11:11 am
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
- Jul 17th, 2026 2:11 pm
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
- Jul 17th, 2026 8:28 am
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
- Jul 14th, 2026 9:57 am
Agenus stock doubles as biotech narrows Phase 3 bet
- Jul 14th, 2026 8:17 am
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
- Jul 14th, 2026 6:15 am
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
- Jul 14th, 2026 4:15 am
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment
- Jul 13th, 2026 12:25 pm
Agenus shares surge as company secures up to $340M to advance colon cancer trial
- Jul 13th, 2026 10:53 am
Scroll